130A Veritas In Silico
- 871
- +1+0.11%
Veritas In Silico News
Veritas In Silico: Fiscal Year Ending December 2024, 3rd Quarter, Financial Results
Veritas In Silico: Organizational Reforms and Personnel Changes of General Managers
Veritas In Silico: Notice regarding organizational reforms and personnel changes (department manager level)
Veritas In Silico: Presentation of financial results for the 3rd quarter of the fiscal year ending 2024/12
Veritas In Silico: Non-consolidated Financial Results for the Nine Months Ended September 30, 2024 [Under Japanese GAAP]
Veritas In Silico: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Veritas In Silico: Correction report (Large shareholding report / Change report)
Veritas In Silico: Mitsubishi Gas Chemical and Veritas In Silico, Sign MOU on Joint Business of Research and Development of RNA-Targeted Drugs
Veritas In Silico: Mitsubishi Gas Chemical and Veritas In Silico sign MOU for joint venture to develop pharmaceuticals targeting RNA
Veritas In Silico: Liverpool ChiroChem and Veritas In Silico Agree to Form a Strategic Partnership of mRNA-Targeted Drug Discovery and Development
Veritas In Silico: Notice of partnership agreement with Liverpool Chirochem in the UK regarding joint drug discovery business for small molecule drugs targeting mRNA
Veritas In Silico: Notification regarding Achievement of Milestone in Joint Drug Discovery Research with Shionogi & Co., Ltd.
Veritas In Silico: Notice of milestone achievement due to progress in joint drug discovery research with Shionogi Pharmaceutical Co., Ltd.
Veritas In Silico: Change Report
Veritas In Silico: [Delayed] Interim Financial Results - FY2024 1H
Veritas In Silico: Half Year Report - Term 9 (2024/01/01 - 2024/12/31)
Veritas In Silico: Confirmation letter
Veritas In Silico: Fiscal year ending December 2024, 2nd quarter (interim) financial results presentation materials for the 9th period.
Veritas In Silico: Short message on accounting settlement for the 2nd quarter (interim period) of fiscal year ending December 2024 [Japanese standard] (non-consolidated).
Veritas In Silico: Unconsolidated financial statements for the six-month period ending June 30, 2024 [based on Japanese accounting standards]
Analysis
Price Target
No Data
No Data